CEN BIOTECH INC (CENBF) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
300-3295 QUALITY WAY WINDSOR, ON N8T 3R9 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2022 MRQ | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 193 | 2 | 4 | 3 | 85 | 62 | |||
| Cash and cash equivalents | 193 | 2 | 4 | 3 | 85 | 62 | |||
| Receivables | 228 | 18 | |||||||
| Other undisclosed current assets | 51 | ||||||||
| Total current assets: | 472 | 20 | 4 | 3 | 85 | 62 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 138 | 229 | ✕ | ✕ | ✕ | ||||
| Property, plant and equipment | 97 | 148 | 167 | 15 | 16 | ||||
| Long-term investments and receivables | 1,344 | 1,224 | 1,110 | 45 | 45 | ||||
| Due from related parties | 1,344 | 1,224 | 1,110 | 45 | 45 | ||||
| Intangible assets, net (including goodwill) | 6,386 | 4,956 | 5,381 | 5,806 | 6,231 | 2,320 | |||
| Goodwill | 1,314 | ||||||||
| Intangible assets, net (excluding goodwill) | 5,072 | 4,956 | 5,381 | 5,806 | 6,231 | 2,320 | |||
| Deferred costs | 217 | ||||||||
| Deferred income tax assets | 3 | ✕ | ✕ | ✕ | |||||
| Other undisclosed noncurrent assets | 114 | 1,695 | |||||||
| Total noncurrent assets: | 7,969 | 6,294 | 6,869 | 6,017 | 6,507 | 4,032 | |||
| Other undisclosed assets | 424 | 1,294 | 2,429 | ||||||
| TOTAL ASSETS: | 8,441 | 6,314 | 7,296 | 7,315 | 9,021 | 4,094 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 2,440 | 1,957 | 10,341 | 7,469 | 4,929 | 3,715 | |||
| Interest and dividends payable | ✕ | 1,362 | 1,125 | 9,585 | 6,860 | 4,541 | 2,717 | ||
| Accounts payable | 440 | 191 | 181 | 207 | 93 | 157 | |||
| Accrued liabilities | 638 | 641 | 575 | 402 | 296 | 841 | |||
| Debt | 4,021 | 7,707 | 15,307 | 13,705 | 11,444 | 19,925 | |||
| Due to related parties | 2,803 | 1,372 | 1,363 | 1,361 | 12 | 63 | |||
| Other undisclosed current liabilities | 597 | 3,670 | 3,858 | 1,873 | 3,642 | (9,009) | |||
| Total current liabilities: | 9,861 | 14,706 | 30,868 | 24,408 | 20,027 | 14,694 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 238 | 220 | 1,223 | 1,546 | 2,208 | 1,392 | |||
| Long-term debt, excluding current maturities | 32 | 78 | 1,039 | 1,546 | 2,208 | 1,392 | |||
| Liabilities, other than long-term debt | 300 | ||||||||
| Due to related parties | 300 | ||||||||
| Operating lease, liability | 207 | 142 | 184 | ✕ | ✕ | ✕ | |||
| Other undisclosed noncurrent liabilities | (207) | 1,238 | 556 | 2,622 | 5,500 | 1,388 | |||
| Total noncurrent liabilities: | 238 | 1,600 | 1,963 | 4,168 | 8,008 | 2,780 | |||
| Total liabilities: | 10,099 | 16,306 | 32,832 | 28,576 | 28,036 | 17,474 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (1,658) | (9,992) | (25,535) | (21,261) | (19,015) | (13,390) | |||
| Preferred stock | 0 | ||||||||
| Common stock | 0 | ||||||||
| Additional paid in capital | 44,340 | 17,069 | 15,775 | 14,394 | 9,110 | 10 | |||
| Accumulated other comprehensive loss | (34) | ||||||||
| Accumulated deficit | (45,964) | (27,061) | (41,310) | (35,655) | (28,125) | (13,390) | |||
| Other undisclosed equity, attributable to parent | (10) | ||||||||
| Other undisclosed equity | 10 | ||||||||
| Total equity: | (1,658) | (9,992) | (25,535) | (21,261) | (19,015) | (13,380) | |||
| TOTAL LIABILITIES AND EQUITY: | 8,441 | 6,314 | 7,296 | 7,315 | 9,021 | 4,094 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2022 TTM | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 627 | 2 | ||||||
| Gross profit: | 627 | 2 | ||||||
| Operating expenses | (19,664) | (2,544) | (2,580) | (4,371) | (11,614) | (5,981) | ||
| Other undisclosed operating loss | (2) | |||||||
| Operating loss: | (19,038) | (2,544) | (2,580) | (4,371) | (11,614) | (5,981) | ||
| Nonoperating income (expense) | 98 | 16,793 | (3,075) | (3,160) | (2,466) | (1,601) | ||
| Gain (loss), foreign currency transaction, before tax | (28) | (55) | (66) | 92 | (89) | (48) | ||
| Interest and debt expense | (419) | (443) | (450) | (431) | (336) | (288) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (19,359) | 13,806 | (6,105) | (7,961) | (14,417) | (7,870) | ||
| Other undisclosed income from continuing operations before income taxes | 419 | |||||||
| Income (loss) from continuing operations before income taxes: | (18,940) | 13,806 | (6,105) | (7,961) | (14,417) | (7,870) | ||
| Income tax benefit | 36 | |||||||
| Income (loss) from continuing operations: | (18,904) | 13,806 | (6,105) | (7,961) | (14,417) | (7,870) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | (18,904) | 13,806 | (6,105) | (7,961) | (14,417) | (7,870) | |
| Net income (loss): | (18,904) | 13,806 | (6,105) | (7,961) | (14,417) | (7,870) | ||
| Other undisclosed net income attributable to parent | 443 | 450 | 431 | 336 | 288 | |||
| Net income (loss) available to common stockholders, basic: | (18,904) | 14,250 | (5,655) | (7,530) | (14,080) | (7,582) | ||
| Dilutive securities, effect on basic earnings per share | 585 | |||||||
| Net income (loss) available to common stockholders, diluted: | (18,904) | 14,835 | (5,655) | (7,530) | (14,080) | (7,582) | ||
Comprehensive Income ($ in thousands)
| 9/30/2022 TTM | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (18,904) | 13,806 | (6,105) | (7,961) | (14,417) | (7,870) | ||
| Comprehensive income (loss): | (18,904) | 13,806 | (6,105) | (7,961) | (14,417) | (7,870) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (34) | |||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (18,938) | 13,806 | (6,105) | (7,961) | (14,417) | (7,870) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.